Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-000016-28
    Sponsor's Protocol Code Number:212483
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-06-23
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-000016-28
    A.3Full title of the trial
    A Phase IIb, randomized, double-blind, parallel-group study to assess the efficacy, safety, tolerability, and resistance profile of GSK3640254 in combination with dolutegravir compared to dolutegravir plus lamivudine in HIV-1 infected, treatment-naïve adults
    Estudio de fase IIb, aleatorizado, con doble enmascaramiento, de grupos paralelos para evaluar la eficacia, la seguridad, la tolerabilidad y el perfil de resistencia de GSK3640254 en combinación con dolutegravir en comparación con dolutegravir más lamivudina en adultos infectados por el VIH-1 sin tratamiento previo
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase IIb Clinical Trial of GSK3640254 + Dolutegravir (DTG) in HIV-1 Infected Treatment-Naive Adults
    Estudio de fase IIb de GSK3640254 + Dolutegravir (DTG) en adultos infectados por el VIH-1 sin tratamiento previo
    A.3.2Name or abbreviated title of the trial where available
    DYNAMIC
    DYNAMIC
    A.4.1Sponsor's protocol code number212483
    A.5.4Other Identifiers
    Name:IND NumberNumber:139838
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorViiV Healthcare UK Limited
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportViiV Healthcare UK (No. 4) Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGlaxoSmithKline Research & Development Ltd.
    B.5.2Functional name of contact pointGSK Clinical Support HelpDesk
    B.5.3 Address:
    B.5.3.1Street Address980 Great West Road
    B.5.3.2Town/ cityBrentford, Middlesex
    B.5.3.3Post codeTW8 9GS
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number004402089904466
    B.5.6E-mailGSKClinicalSupportHD@gsk.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGSK3640254
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot Available
    D.3.9.1CAS number 1818867-24-1
    D.3.9.2Current sponsor codeGSK3640254
    D.3.9.3Other descriptive nameGSK3640254D where D denotes the methanesulfonate salt
    D.3.9.4EV Substance CodeSUB218087
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGSK3640254
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot Available
    D.3.9.1CAS number 1818867-24-1
    D.3.9.2Current sponsor codeGSK3640254
    D.3.9.3Other descriptive nameGSK3640254D where D denotes the methanesulfonate salt
    D.3.9.4EV Substance CodeSUB218087
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Tivicay
    D.2.1.1.2Name of the Marketing Authorisation holderViiV Healthcare BV
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTivicay 50 mg film-coated tablets
    D.3.2Product code Not Applicable
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDolutegravir
    D.3.9.1CAS number 1051375-19-9
    D.3.9.2Current sponsor codeNot Applicable
    D.3.9.3Other descriptive nameDOLUTEGRAVIR
    D.3.9.4EV Substance CodeSUB35122
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Epivir
    D.2.1.1.2Name of the Marketing Authorisation holderViiV Healthcare BV
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameOver-encapsulated Epivir® (Lamivudine) Tablets
    D.3.2Product code Not Applicable
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLAMIVUDINE
    D.3.9.1CAS number 134678-17-4
    D.3.9.2Current sponsor codeNot Applicable
    D.3.9.3Other descriptive nameLamivudine
    D.3.9.4EV Substance CodeSUB08392MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Epivir
    D.2.1.1.2Name of the Marketing Authorisation holderViiV Healthcare BV
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEpivir 300 mg film-coated tablets
    D.3.2Product code Not Applicable
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLAMIVUDINE
    D.3.9.1CAS number 134678-17-4
    D.3.9.2Current sponsor codeNot Applicable
    D.3.9.3Other descriptive nameLamivudine
    D.3.9.4EV Substance CodeSUB08392MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Human Immunodeficiency Virus Type-1 (HIV-1)
    Virus de Inmunodeficiencia Humana Tipo 1 (VIH-1)
    E.1.1.1Medical condition in easily understood language
    HIV infection
    Infección por VIH
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10068341
    E.1.2Term HIV-1 infection
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate antiviral efficacy of GSK3640254 + DTG, relative to DTG + 3TC at Week 24 in HIV-1 infected, ART-naïve participants
    Evaluar la eficacia antiviral de GSK3640254 + DTG en comparación con DTG + 3TC en la Semana 24 en participantes infectados por VIH-1 sin TARV previo
    E.2.2Secondary objectives of the trial
    • To evaluate the antiviral activity of GSK3640254 + DTG relative to DTG + 3TC at Week 48;
    • To evaluate safety and tolerability of GSK3640254 when given in combination with DTG, relative to DTG + 3TC;
    • To assess the development of viral resistance to GSK3640254 and other on-study ART in participants experiencing virologic failure through Week 48;
    • To assess the steady-state exposure of GSK3640254 when given in combination with DTG.
    • Evaluar la actividad antivírica de GSK3640254 + DTG en comparación con DTG + 3TC en la Semana 48;
    • Evaluar la seguridad y la tolerabilidad de GSK3640254 cuando se administra en combinación con DTG, en comparación con DTG + 3TC;
    • Evaluar el desarrollo de la resistencia viral a GSK3640254 y otros TARV durante el estudio en participantes que experimenten un fracaso virológico hasta la Semana 48;
    • Evaluar la exposición en estado de equilibrio de GSK3640254 cuando se administra en combinación con DTG.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Age:
    1. Participants must be 18 years of age inclusive, at the time of signing the informed consent.
    Type of Participant and Disease Characteristics:
    2. Treatment-naïve, defined as no ARVs (in combination or monotherapy) received after a known diagnosis of HIV-1 infection;
    NOTE: Use of PrEP (prior to known HIV-1 infection) is allowed and still meets inclusion. PrEP is used by individuals who are not infected with HIV-1 but who are at high risk for acquiring the virus. PrEP alone is not sufficient to treat HIV and the use of PrEP is stopped if/when a diagnosis of HIV is made.
    3. Documented HIV infection and Screening plasma HIV-1 RNA ≥1000 c/mL;
    4. Screening CD4+ T-cell count ≥300 cells/mm3;
    Weight:
    5. Body weight ≥50.0 kg (110 lbs.) for men and ≥45.0 kg (99 lbs) for women and body mass index (BMI) > 18.5 kg/m2. Calculations will utilize sex assigned at birth;
    Sex:
    Sex and Contraceptive/Barrier Requirements:
    6. Male and female
    a. Participants who are male at birth: There are no contraceptive requirements for participants who are male at birth
    b. Participants who are female at birth:
    Contraceptive use by participants who are female at birth should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
    • A participant who is female at birth is eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:
    o Is not a participant of childbearing potential (PONCBP) as defined in Section 10.4.
    OR
    o Is a POCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, as described in Section 10.4 during the study intervention period and until after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.
    o If a hormonal method is selected, the participant is required to be clinically stable on it for at least one month prior to starting treatment in the study.
    • A POCBP must have a negative highly sensitive serum pregnancy test at Screening and a negative urine pregnancy test at Day 1 before starting study intervention .
    o If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
    • Additional requirements for pregnancy testing during and after study intervention are located in Section 8.2.5 Pregnancy Testing.
    • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a participant with an early undetected pregnancy Informed Consent:
    7. Capable of giving signed informed consent as described in Section 10.1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
    Other:
    8. For participants enrolled in France: a participant will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
    Edad:
    1. Los participantes deben ser mayores de 18 años inclusive, en el momento de firmar el consentimiento informado.
    Tipo de participante y características de la enfermedad:
    2. Sin tratamiento previo, lo que se define como no haber recibido TARV (en combinación o en monoterapia) tras un diagnóstico conocido de infección por VIH-1;
    NOTA: se permite y cumple por tanto el criterio de inclusión el uso de PrEP (con anterioridad a la infección por VIH-1 conocida). La PrEP la utilizan personas que no están infectadas por el VIH-1, pero que tienen un alto riesgo de contraer el virus. La PrEP en monoterapia no es suficiente para tratar el VIH y su uso se suspende si/cuando se diagnostica el VIH.
    3. Infección por VIH documentada y un valor de ARN del VIH-1 plasmático en la selección ≥1000 c/mL;
    4. Recuento de células T CD4+ en la selección ≥300 células/mm3;
    Peso:
    5. Peso corporal ≥50,0 kg (110 libras) para hombres y ≥45,0 kg (99 libras) para mujeres, e índice de masa corporal (IMC) >18,5 kg/m2. En los cálculos se utilizará el sexo asignado al nacer;
    Sexo:
    Sexo y requisitos sobre métodos anticonceptivos:
    6. Masculino y femenino
    a. Participantes masculinos al nacer: no hay requisitos sobre métodos anticonceptivos para los participantes masculinos al nacer.
    b. Participantes femeninas al nacer:
    El uso de anticonceptivos por parte de las participantes con sexo femenino al nacer debe ser acorde a la normativa local relativa a los métodos anticonceptivos para sujetos participantes en estudios clínicos.
    • Las participantes con sexo femenino al nacer podrán participar en el estudio si no están embarazadas o dando el pecho y cumplen una de las condiciones siguientes:
    o No ser una participante fértil según lo definido en el apartado 10.4.
    O
    o Ser una participante fértil y utilizar un método anticonceptivo de alta eficacia (con una tasa de fracaso <1% al año), con baja dependencia del usuario, según lo descrito en el apartado 10.4, durante el periodo intervencional del estudio y hasta después de la última dosis de la intervención del estudio. El investigador debe evaluar el potencial de fracaso del método anticonceptivo (por ejemplo, incumplimiento, inicio reciente) en relación con la primera dosis de la intervención del estudio.
    o Si se selecciona un método hormonal, la participante debe estar clínicamente estable con él durante al menos un mes antes de iniciar el tratamiento del estudio.
    • Una participante fértil debe tener una prueba de embarazo en suero de alta sensibilidad negativa en la selección y una prueba de embarazo en orina negativa el día 1 antes de iniciar la intervención del estudio.
    o Si la prueba en orina no puede confirmarse como negativa (por ejemplo, en caso de resultado ambiguo), será necesaria una prueba de embarazo en suero. En tales casos, la participante debe ser excluida de la participación si el resultado de la prueba de embarazo en suero es positivo.
    • Se indican requisitos adicionales de pruebas de embarazo durante y después de la intervención del estudio en el apartado 8.2.5 Pruebas de embarazo.
    • El investigador es responsable de revisar los antecedentes médicos y menstruales y la actividad sexual reciente para mitigar el riesgo de inclusión de una participante con un embarazo temprano no detectado. Consentimiento informado:
    7. Capacidad para proporcionar un consentimiento informado firmado según lo descrito en el apartado 10.1, lo que incluye el cumplimiento de los requisitos y restricciones enumerados en el formulario de consentimiento informado (FCI) y en este protocolo.
    Otros:
    8. Para los participantes inscritos en Francia: un participante solo puede ser elegible para inclusión en este estudio si está afiliado o es beneficiario de alguna categoría de la Seguridad Social.
    E.4Principal exclusion criteria
    1.Evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3 disease [CDC, 2014], except cutaneous Kaposi’s sarcoma not requiring systemic therapy
    2.Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia
    3.Presence of primary HIV infection, evidenced by acute retroviral syndrome (e.g., fever, malaise, fatigue...) and/or evidence of recent (within 3M) documented viremia without antibody production and/or evidence of recent (within 3M) documented seroconversion
    4.Known history of liver cirrhosis with/without viral hepatitis co-infection
    5. Unstable liver disease (as defined by: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment)
    6.History of ongoing or clinically relevant hepatitis within the previous 6M
    7.History of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation
    8.History of significant underlying psychiatric disorder, in the opinion of the Investigator or Medical Monitor, including but not limited to schizophrenia, bipolar disorder with/without psychotic symptoms, other psychotic disorders, or schizotypal disorder; or clinical assessment of suicidality based on the responses on the CSSRS
    9.History of major depressive disorder with/without suicidal features, or anxiety disorders, that required medical intervention (pharmacologic or not) such as hospitalization or other inpatient treatment and/or chronic (>6M) outpatient treatment
    10.Pre-existing physical or other psychiatric condition (including alcohol or drug abuse), which, in the opinion of the Investigator or Medical Monitor (with/without psychiatric evaluation), could interfere with the participant’s ability to comply with the dosing schedule and protocol evaluations or which might compromise the safety of the participant
    11.Pre-existing condition, in the opinion of the Investigator or Medical Monitor, that could interfere with normal gastrointestinal anatomy or motility (e.g., GERD, gastric ulcers, gastritis, inflammatory bowel disease), hepatic and/or renal function, or with the absorption, metabolism, and/or excretion of the study interventions or render the participant unable to take oral study treatment
    12.Myocardial infarction, acute coronary syndrome, unstable angina, stroke, transient ischemic attack, or intermittent claudication in the past 3M
    13.Familial or personal history of long QT syndrome or sudden cardiac death
    14.Medical history, current or historical, of significant cardiac arrhythmias or ECG findings which, in the opinion of the Investigator or Medical Monitor, will interfere with the safety of the participant
    15.Active treatment for a viral infection other than HIV-1, such as Hepatitis B, with an agent that is active against HIV-1 (were known to be infected with HIV-1 after treatment for Hepatitis B was completed)
    16.Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening
    17.Treatment with any of the following agents within 28 days of Screening: radiation therapy, cytotoxic chemotherapeutic agents, any systemic immune suppressant
    18.Participants receiving protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication
    19.Participants who require concomitant medications known to be associated with a prolonged QTc
    20. Exposure to an experimental drug, human blood product, monoclonal antibody, or vaccine (which does not have emergency, conditional, or market authorization) within 28 days prior to the 1 dose of study treatment
    21.Current enrollment or past participation within the last 30 days before signing of consent in any other clinical study involving an investigational study intervention (including investigational COVID vaccine) or any other type of medical research
    22.Historical evidence (prior screening period) of the presence of resistance-associated mutations gag A364V or A364A/V
    23.Creatinine Clearance <50 mL/min
    24.ALT ≥ 3x ULN or ALT ≥ 2x ULN and total bilirubin ≥ 1.5x ULN (upper limit of normal)
    25.Evidence of Hepatitis B virus (HBV) infection based on the results of testing for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antibody (anti-HBs) and reflex HBV DNA;
    For full list of exclusion criteria, please refer to the protocol
    1.Evidencia de enf. activa en estadio 3 de los Centros para la prevención y el control de enf. (CDC, 2014), exep. sarcoma cutáneo de Kaposi que no requiera trat. sistémico
    2.Cáncer en curso que no sea sarcoma cutáneo de Kaposi, carcinoma basocelular, o carcinoma de células escamosas de la piel resecado, no invasivo, o neoplasia intraepitelial de cérvix, ano o pene
    3.Presencia de infección primaria por VIH, evidenciada por un sínd. retroviral agudo (fiebre, malestar, fatiga...) o evidencia de viremia sin producción de anticuerpos reciente (últimos 3M) documentada o evidencia de seroconversión reciente (últimos 3M) documentada
    4.Antecedentes conocidos de cirrosis hepática con/sin coinfección por hepatitis vírica
    5.Enf. hepática inestable (definida: presencia de ascitis, encefalopatía, coagulopatía, hipoalbuminemia, varices esofágicas o gástricas, o ictericia persistente o cirrosis ), anomalías biliares conocidas (excep. Sínd. de Gilbert o cálculos biliares asintomáticos o enf. hepática crónica pero estable a juicio del investigador)
    6.Antecedentes de hepatitis en curso o clínicamente relevante en los 6M previos
    7.Antecedentes de alergia medicamentosa o de otro tipo que, en opinión del investigador o monitor médico, contraindique la participación
    8.Antecedentes de trast. psiquiátrico subyacente significativo, en opinión del investigador o monitor médico, incluidos pero sin limite a esquizofrenia, trast. bipolar con/sin síntomas psicóticos, otros trast. psicóticos, o trast. esquizotípico; o eval. clínica de existencia de riesgo suicida en base a las respuestas al cuestionario CSSRS
    9.Antecedentes de trast. depresivo mayor con/sin cuadro suicida, o trast. de ansiedad, que requiriera intervención médica (farmacológica o no) tal como hospitalización u otro trat. hospitalario o ambulatorio crónico (>6M)
    10.Trast. físico o psiquiátrico de otro tipo preexistente (incl. abuso alcohol o drogas) que, en opinión del investigador o monitor médico (con/sin evaluación psiquiátrica) pudiera interferir con la capacidad del participante para cumplir con la pauta farmacológica y las evaluaciones del protocolo o que pudiera poner en peligro la seguridad del participante
    11.Trast. preexistente que, en opinión del investigador o monitor médico, pudiera interferir con la anatomía o motilidad gastrointestinal normal (p.e. ERGE, úlceras gástricas, gastritis, enf. intest. inflamatoria), función hepática o renal, o con la absorción, el metabolismo o la excreción de las intervenciones del estudio o hacer al participante incapaz de tomar el trat. oral del estudio
    12.Infarto de miocardio, síndr. coronario agudo, angina inestable, accidente cerebrovascular, accidente isquémico transitorio o claudicación intermitente en los últimos 3M
    13.Antecedentes familiares o personales de sínd. de QT largo o muerte cardiaca súbita
    14.Hª médico, presente o pasado, de arritmias cardiacas significativas o hallazgos en ECG que, en opinión del investigador o monitor médico, puedan interferir con la seguridad del participante
    15.Trat. activo para una inf. vírica distinta del VIH-1, tal como hepatitis B, con un agente que tenga actividad contra el VIH-1 (infección por VIH-1 se conoció tras completarse el trat. para la hepatitis B)
    16.Trat. con una vacuna inmunoterapéutica contra el VIH-1 en los 90 días anteriores a la selección
    17.Trat. con cualquiera de los agentes siguientes en los 28 días anteriores a la selección: radioterapia, quimioterapia antineoplásica, cualquier inmunosupresor sistémico
    18.Participantes que estén recibiendo medic. prohibido por el protocolo y no quieran o no puedan cambiar a otro medicamento alternativo
    19.Participantes que requieran medic. concomitantes que se sepa que están asociados con una prolongación del QTc
    20.Exposición a un fco, hemoderivado, anticuerpo monoclonal o vacuna experimental (no tenga autorización de uso de emergencia, condicional o de comercialización) en los 28 días anteriores a la 1 dosis del trat. del estudio
    21.Inscripción actual o participación pasada en los 30 días anteriores a la firma del consentimiento en cualquier otro estudio clínico que incluya una intervención del estudio de carácter investig. (incluida vacuna para la COVID en investigación) o cualquier otro tipo de investigación médica
    22.Evidencia Hª (previa a periodo de selección) de la presencia de mutaciones en gag asociadas a resistencia A364V o A364A/V
    23.Aclaramiento de creatinina <50 mL/min
    24.ALAT ≥3 veces el LSN o ALAT ≥2 veces el LSN y bilirrubina total ≥1,5 veces el LSN (límite superior de la normalidad)
    25.Evidencia infección por virus de hepatitis B (VHB) basada en los resultados de pruebas de antígeno de superficie de la hepatitis B (HBsAg), anticuerpo contra el antígeno central de la hepatitis B (anti-HBc), anticuerpo contra el antígeno de superficie de la hepatitis B (anti-HBs) y pruebas adicionales de ADN del VHB cuando proceda
    Para obtener la lista completa de criterios de exclusión, consulte el protocolo
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of participants with plasma HIV-1 RNA <50 c/mL at Week 24 using the FDA snapshot algorithm
    Proporción de participantes con ARN del VIH-1 plasmático <50 c/mL en la semana 24 utilizando el algoritmo de instantáneas de la FDA
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 24
    Semana 24
    E.5.2Secondary end point(s)
    • Proportion of participants with plasma HIV-1 RNA <50 c/mL at Week 48 using the FDA snapshot algorithm;
    • Absolute values and changes from baseline in HIV-1 RNA through Weeks 24 and 48;
    • Absolute values and changes from baseline in CD4+ T-cell counts through Weeks 24 and 48;
    • Frequency of SAEs, Deaths and AEs leading to Discontinuation through Weeks 24 and 48;
    • AEs of special interest (AESIs) through Weeks 24 and 48;
    • Changes in genotypic and/or phenotypic profiles of virus compared to baseline;
    • The steady-state plasma PK parameters of GSK3640254 will be assessed based on Sparse PK sampling through Week 48
    • Proporción de participantes con ARN del VIH-1 plasmático <50 c/mL en la Semana 48 utilizando el algoritmo de instantáneas de la FDA;
    • Valores absolutos y cambios en el ARN del VIH-1 desde el momento basal hasta las Semanas 24 y 48;
    • Valores absolutos y cambios en el recuento de células T CD4+ desde la el momento basal hasta las Semanas 24 y 48;
    • Frecuencia de AAG, muertes y AA conducentes a discontinuación hasta las Semanas 24 y 48;
    • AA de interés especial (AAIE) hasta las Semanas 24 y 48;
    • Cambios en los perfiles genotípicos o fenotípicos del virus en comparación con el momento basal;
    • Los parámetros FC del plasma en estado de equilibrio de GSK3640254 se evaluarán con base en el muestreo FC disperso hasta la Semana 48
    E.5.2.1Timepoint(s) of evaluation of this end point
    Please refer to the time period specified in E.5.2 Secondary end point section.
    Consulte el periodo especificado en el apartado E.5.2 Criterio de valoración secundario.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability, Resistance profile, Viral Genotyping and Phenotyping Analyses
    Análisis de tolerabilidad, perfil de resistencia, genotipo y fenotipo del virus
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned16
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA31
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Puerto Rico
    Russian Federation
    South Africa
    United States
    France
    Germany
    Italy
    Poland
    Portugal
    Spain
    Argentina
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the date of the last visit of the last participant in the study.
    A participant is considered to have completed the study if the participant has completed all phases of the study including the last visit.
    El final del estudio se define como la fecha de la última visita del último participante en el estudio.
    Se considera que un participante ha completado el estudio si el participante ha completado todas las fases del estudio, incluida la última visita.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months4
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 90
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 30
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state48
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 55
    F.4.2.2In the whole clinical trial 120
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    To provide continued access to an unapproved investigational drug to participants deriving additional therapeutic benefit not expected from locally available standard of care, participants that received GSK3640254 + DTG and who have successfully completed 52 weeks of treatment will be given the opportunity to continue to receive GSK3640254 + DTG as per the protocol conditions until GSK3640254 + DTG is commercially available
    Para proporcionar el acceso continuado a un medicamento no aprobado en fase de investigación a los participantes que obtengan de él un beneficio terapéutico adicional que no sea esperable de la atención convencional disponible localmente, a los participantes que recibieron GSK3640254 + DTG y que han completado con éxito 52 semanas de trat. se les dará la oportunidad de seguir recibiendo GSK3640254 + DTG según las condiciones del protocolo hasta que GSK3640254 + DTG esté disponible comercialmente
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-08-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-06-18
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:20:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA